- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06392360
Betaine, Exercise Performance, and Gut Permeability
Influence of 2-Weeks DuraBeet® Ingestion on Cycling Performance, Gut Permeability, and Metabolite Shifts
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will employ a randomized crossover design. Study participants will be randomized to two trials using double-blinded, placebo-controlled procedures. The supplement capsules (betaine and placebo) will be coded by the sponsor, with the double-blind code held until after all study samples have been analyzed. Subjects will come to the lab for orientation/baseline testing, pre-and post-supplementation blood sample collections (2 weeks supplementation with betaine or placebo), two 60-km cycling sessions, and two 24-h recovery lab sessions (thus 8 total lab visits). Subjects will complete a COVID-19 screening questionnaire before entering the lab (all visits). The total amount of time subjects will be asked to volunteer for this study is about 18 hours at the Human Performance Laboratory (over a 6-week period).
A. Orientation (Visit #1). Subjects will report to the lab in an overnight fasted state. Subjects will voluntarily sign IRB-approved consent forms and complete questionnaires (delayed onset of muscle soreness or DOMS, Profile of Mood States or POMS). Demographic, health, and training histories will be acquired with questionnaires. A blood sample will be collected. Body composition and total body water will be measured using 8-point bioelectrical impedance (BIA). Subjects will ingest a standardized sugar solution containing lactulose 5 g, 13C mannitol 100 mg, mannitol 1.9 g, and rhamnose 1 g in a total of 450 ml water (SS, calculated osmolality 69 mosmol/kg). An increase in the post-exercise lactulose/13C mannitol ratio (L/M) will be used as an indicator of increased gut permeability. All urine excreted for five hours post SS ingestion will be collected in a urine collection container. Subjects will be urged to drink water after the first hour of the test to ensure adequate urine output. The Boost beverage will be consumed at 7 kcal/kg 1.5 h post SS ingestion (to simulate what occurs post-exercise). The urine collection container will be placed in the refrigerator until they are returned to the lab the next day. The total urine volume will be measured with four 10 ml aliquots frozen in a minus 80°C freezer until analysis.
B. Baseline Testing/Pre-Supplementation (Visit #2). Subject will return the urine collection container to the lab the day after Visit #1. Body composition will be measured with the Bod Pod body composition analyzer (Life Measurement, Concord, CA). Study participants will be tested for maximal aerobic capacity (VO2max) during a graded, cycling test with continuous metabolic monitoring with the Cosmed CPET metabolic device (Cosmed, Rome, Italy). A 2-week supply of betaine or placebo capsules will be given to the participants. Subjects will consume 6 capsules per day, 3 with the first meal in the morning and 3 more with the last meal of the day.
DuraBeet Betaine supplement. DuraBeet® crystalline betaine is produced from beet molasses at the betaine crystallization plant, in Austria, according to strict European standards. The white crystalline betaine will be in 6 capsules (3 g/day). The placebo capsules will contain a white cellulose powder in identical looking capsules.
C. 60-km Cycling Session (Lab Visit #3): During the 3-day period prior to the 60-km cycling session, subjects will taper exercise training and ingest a moderate-carbohydrate diet using a food list restricting high fat foods, visible fats, and caffeine. Subjects will record all food and beverage intake in a 3-day food record with macro- and micro-nutrient intake calculated using the ESHA Food Processor nutrient analysis software program. Study participants will report to the Human Performance Lab in an overnight fasted state and provide a blood sample, ingest the supplement (3 capsules of betaine or placebo), and then cycle 60-km at the fastest pace possible while ingesting water alone (3 ml/kg every 15 minutes). Immediately following the cycling bout, subjects will ingest the gut permeability sugar solution (SS). Blood samples will be collected at 0 h, 1.5 h, 3.0 h, and 24-h post-exercise. All urine excreted for five hours after SS ingestion will be collected in a urine collection container.
Testing protocol during the lab sessions with the 60-km cycling session:
- 7:00 am: Provide blood sample, delayed onset of muscle soreness (DOMS) rating (1-10 scale), and profile of mood states ratings (POMS). Complete the symptom survey. Turn in the 3-day food record.
- 7:10 am: Ingest 3 capsules of betaine or placebo with 1 cup water.
- 7:30 am: Start the 60-km cycling session. Subjects will cycle on trainers at race pace for 60-km. Oxygen consumption, carbon dioxide production, respiratory exchange ratio, and ventilation will be measured using the Cosmed Quark CPET metabolic cart every 30 minutes. Subjects will consume 3 ml/kg water every 15 min. No other beverage or food containing energy or nutrients will be allowed during the 60-km exercise sessions.
- ~10:00 am to 1:00 pm: Subjects will ingest the 450 mL SS within the first minute of getting off the bicycle. Body composition and total body water will be measured using 8-point bioelectrical impedance (BIA). All urine excreted from 0-5 h after SS ingestion will be collected in a urine collection container. Blood samples will be taken via venipuncture immediately after completing the cycling session, and then 1.5-h, 3.0-h, and 24-h post-exercise. Subjects will be allowed to shower and change clothes. The DOMS and POMS questionnaires will be administered each time blood samples are collected. Body composition and total body water will be measured using 8-point BIA each time blood samples are collected. Subjects will ingest no food or beverage other than water (7 ml/kg during the 1.5 h post-exercise period; this will take into account the 450 ml sugar solution; no water will be ingested during the first hour post-SS intake). After the 1.5 h post-exercise blood draw, subjects will ingest a Boost beverage (7 kcal/kg body weight). Another blood sample will be collected 3-h post-exercise. Afterwards, subjects will leave the lab with instructions to complete the 5h urine collection, put the container in the refrigerator, and then bring the urine container to the lab the next morning. Subjects will ingest 3 supplement capsules with the last meal of the day.
LAB VISIT #4: Subjects will return the next morning after the cycling session to provide another blood sample, turn in the 5-h urine container, and complete DOMS and POMS questionnaires. Body composition and total body water will be measured using 8-point BIA.
D. Washout/Crossover/Repeat
Subjects will engage in a 2-week washout period without the supplements, crossover to the opposite supplement arm, and then repeat all procedures except for the consent process, completion of the medical health questionnaire, body composition testing, and VO2 max testing (Lab visits #5,6,7,8). Subjects will maintain the study diet and normal exercise training routines during the 2-week washout period.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: David C Nieman, DrPH
- Phone Number: 8287730056
- Email: niemandc@appstate.edu
Study Contact Backup
- Name: Camila A Sakaguchi Olson, PhD
- Phone Number: 7042505352
- Email: olsonca1@appstate.edu
Study Locations
-
-
North Carolina
-
Kannapolis, North Carolina, United States, 28081
- Recruiting
- Appalachian State University Human Performance Lab, North Carolina Research Campus
-
Contact:
- Camila A Sakaguchi, PhD
- Phone Number: 7042505352
- Email: olsonca1@appstate.edu
-
Contact:
- David Nieman, DrPH
- Phone Number: 828-773-0056
- Email: niemandc@appstate.edu
-
Principal Investigator:
- David Nieman, DrPH
-
Kannapolis, North Carolina, United States, 28081
- Recruiting
- AppState-North Carolina Research Campus Human Performance Lab
-
Contact:
- David C Nieman, DrPH
- Phone Number: 828-773-0056
- Email: niemandc@appstate.edu
-
Contact:
- Camila A Sakaguchi Olson, PhD
- Phone Number: 7042505352
- Email: olsonca1@appstate.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female cyclists, ages 18-65 years, and capable of cycling 60-km in the laboratory at 70% VO2max (close to race pace).
- Non-smoker, and generally healthy and without gastrointestinal diseases (irritable bowel syndrome, chronic nausea, vomiting, and diarrhea, Crohn's disease, Celiac disease, diverticulosis) or chronic diseases including cardiovascular disease (e.g., heart disease, stroke), cancer, type 1 and 2 diabetes, rheumatoid arthritis. Categorized as "low risk" using the American College of Sports Medicine screening questionnaire.
- Agree to train normally, maintain weight, and avoid the regular use of large-dose vitamin and mineral supplements, herbs, and medications that influence inflammation (especially NSAIDs) for the duration of the 6-week study and at least a 2-week period prior to the study.
- Agree to taper their exercise routine prior to each of the 2 lab cycling sessions.
- Agree to restrict beet, wheat bran, wheat germ, and spinach diet intake and avoid other betaine supplements (other than what is provided in the supplement) during the entire 6-week study.
Exclusion Criteria:
- Inability to comply with study requirements.
- Females trying to become pregnant, or currently pregnant or breastfeeding.
- Nonpregnant adults who weigh less than 110 pounds.
- Any other concurrent condition which, in the opinion of the principal investigator (PI), would preclude participation in this study or interfere with compliance.
- Current diagnosis of gastrointestinal disease, cardiovascular disease, diabetes, or cancer (except for non-melanoma skin cancer).
- History of sensitivity to betaine and beets.
- History of adverse symptoms to lactulose, mannitol, and rhamnose sugars.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Betaine
3 grams per day in 6 capsules, white crystalline betaine powder produced from beet molasses
|
White betaine powder
|
Placebo Comparator: Placebo
3 grams per day in 6 capsules, white cellulose powder
|
White placebo powder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exercise Performance
Time Frame: After 2-weeks supplementation with betaine compared to after 2-weeks supplementation with placebo
|
60-km cycling time trial
|
After 2-weeks supplementation with betaine compared to after 2-weeks supplementation with placebo
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gut permeability
Time Frame: Change from pre-supplementation levels to 5 hours post-exercise
|
Urine concentrations of post-exercise lactulose/13C mannitol ratio (L/M)
|
Change from pre-supplementation levels to 5 hours post-exercise
|
Changes in plasma gut permeability sugars including mannitol, lactulose, rhamnose, and sucrose from targeted metabolomics using LC-MS/MS analysis (relative intensities)
Time Frame: Change from pre-study to post-2 weeks supplementation, and immediately post-exercise, and 1.5 hours-, 3 hours-, and 24 hours-post-exercise
|
Targeted metabolomics to assess plasma metabolites (sugars) from LC-MS/MS analysis (relative intensities) [Time Frame: Change from pre-study to post-2 weeks supplementation, and immediately post-exercise, and 1.5 hours-, 3 hours |
Change from pre-study to post-2 weeks supplementation, and immediately post-exercise, and 1.5 hours-, 3 hours-, and 24 hours-post-exercise
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David C Nieman, DrPH, Appalachian State Univ
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS-24-248
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Disturbance
-
The Swedish School of Sport and Health SciencesActive, not recruiting
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of TorontoCanadian Institutes of Health Research (CIHR)RecruitingSedentary Behavior | Metabolic DisturbanceCanada
-
Northumbria UniversityCompletedMetabolic Disturbance | Dietary ExposureUnited Kingdom
-
Appalachian State UniversityRecruitingGastrointestinal Dysfunction | Metabolic DisturbanceUnited States
-
University of TorontoWomen's College HospitalCompleted
-
University of TorontoCompletedMetabolic DisturbanceCanada
-
Northumbria UniversityUnknownMetabolic Disturbance | Dietary ExposureUnited Kingdom
-
University of NottinghamCompletedObesity | Metabolic DisturbanceUnited Kingdom
Clinical Trials on Betaine
-
University of California, San FranciscoCompleted
-
University of Sao PauloCompleted
-
Southern California Institute for Research and...RecruitingNon-Alcoholic Fatty Liver Disease | Non Insulin Dependent Diabetes | ALTUnited States
-
University of Colorado, DenverCompleted
-
Poznan University of Life SciencesNational Science Centre, PolandUnknown
-
Fundació Sant Joan de DéuNot yet recruitingInfant Growth | Childhood Overweight
-
Michael J. OrmsbeeActive, not recruitingInflammation | Body Temperature Changes | Body Water DehydrationUnited States
-
University of North Carolina, Chapel HillCompletedMale Infertility | Men Carrying 2 Minor Alleles for Choline Dehydrogenase rs12676United States
-
University of California, San FranciscoCompletedPharmacodynamicUnited States
-
Mucosa Innovations, S.L.CompletedOral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.Quality of Life | Pain | Mucositis | Radiation Toxicity | Chemotherapeutic Toxicity | Oral Mucositis | Saliva | SpeechSpain